Rob G J A Zuiker: research papers - The Consciousness Library

Pharmacokinetics, pharmacodynamics and safety of N,N -dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers

Journal of Psychopharmacology August 31, 2026 Katelijne V. van der Heijden, Soma Makai‐bölöni, Amir Inamdar et al.

BACKGROUND: -dimethyltryptamine (DMT) might have therapeutic effects in various psychiatric disorders. AIMS: Prior to exploring this clinical potential, it is essential to determine an optimal administration regimen for DMT, explore the relationship between its pharmacokinetics (PK) and pharmacodynamics and identify potential sources of pharmacokinetic variability. METHODS: Therefore, DMT was...

DOI: 10.1177/02698811261473451

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.

Clinical and Translational Science May 1, 2025 Katelijne V. van der Heijden, Rob G J A Zuiker, Marije E. Otto et al. 7 citations

The serotonergic psychedelic N,N-dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which it may exert neuroprotective effects during acute ischemic stroke. Since neuroplasticity has been implicated in the mechanism of action of rehabilitative therapy in stroke recovery, a pharmacological augmentation strategy facilitating neuroplasticity could be...

DOI: 10.1111/cts.70234 Full text N-dimethyltryptamine N,N‐Dimethyltryptamine Healthy volunteers Intravenousinfusion +10

Administration of oxathridine, a first‐in‐class histamine‐3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo‐hallucinations

British Journal of Clinical Pharmacology September 19, 2023 Francis M. Dijkstra, Rob G J A Zuiker, Jules A A C Heuberger et al. 1 citation

AIMS: To characterise the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of oxathridine, a first-in-class histamine-3 receptor partialagonist, in healthy male volunteers. METHODS: A randomised, double-blind, placebo-controlled study including the NeuroCart, consisting of a battery of drug sensitive neurophysiological tests, was performed....

DOI: 10.1111/bcp.15910

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

Psychopharmacology February 1, 2018 Randall L. Morrison, Maggie Fedgchin, Jaskaran Singh et al. 72 citations

BACKGROUND: The effect of intranasal esketamine on cognitive functioning in healthy participants is assessed in this study. METHODS: computerized test battery assessed at 1 h predose and 40 min, 2, 4, and 6 h postdose. Secondary measures included the Mental Effort Scale, Karolinska Sleepiness Scale (KSS), and safety. RESULTS: Esketamine was associated with significant cognitive performance...

DOI: 10.1007/s00213-018-4828-5 Full text Placebo Anesthesia Crossover study Adverse effect +2

Papers

Pharmacokinetics, pharmacodynamics and safety of N,N -dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.

Administration of oxathridine, a first‐in‐class histamine‐3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo‐hallucinations

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study